Skip to Main Content

Author Details

Aparna A Kamat
Houston Methodist Hospital
2000
66
40
PMIDPaper TitleJournal TitlePublished Year
36077371The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.Int J Mol Sci2022
34341060Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.Clin Cancer Res2021
34799731Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.Nat Med2021
31092618Correction: Focal Adhesion Kinase Targeting Using <i>In vivo</i> Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.Clin Cancer Res2019
31799096Laparoscopic Allograft Spacer Placement to Minimize Bowel Dose During Re-irradiation with Interstitial Brachytherapy.Cureus2019
29193904Somatic mosaicism of an intragenic FANCB duplication in both fibroblast and peripheral blood cells observed in a Fanconi anemia patient leads to milder phenotype.Mol Genet Genomic Med2018
29098742A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families.Hum Mutat2018
28678401Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.Cancer2017
26841305Paternal or Maternal Uniparental Disomy of Chromosome 16 Resulting in Homozygosity of a Mutant Allele Causes Fanconi Anemia.Hum Mutat2016
25903015Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL.Cancer Cytopathol2015
25168418Comprehensive analysis of pathogenic deletion variants in Fanconi anemia genes.Hum Mutat2014
23653574Exome Sequencing and High-Density Microarray Testing in Monozygotic Twin Pairs Discordant for Features of VACTERL Association.Mol Syndromol2013
23613520Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia.Blood2013
22585771Incidental medical information in whole-exome sequencing.Pediatrics2012
22492981Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.Clin Cancer Res2012
21056906Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.Gynecol Oncol2011
21992853Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.Lancet Oncol2011
21608104De novo deletion of chromosome 20q13.33 in a patient with tracheo-esophageal fistula, cardiac defects and genitourinary anomalies implicates GTPBP5 as a candidate gene.Birth Defects Res A Clin Mol Teratol2011
21315191Analysis of FOXF1 and the FOX gene cluster in patients with VACTERL association.Eur J Med Genet2011
20371710Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.Mol Cancer Ther2010
20948320Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.Cancer Biol Ther2010
20145172Frequent downregulation of miR-34 family in human ovarian cancers.Clin Cancer Res2010
20166213Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.Cancer2010
20389021Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.J Clin Invest2010
19058181Functional significance of VEGFR-2 on ovarian cancer cells.Int J Cancer2009
20007585Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A.J Immunol2009
19738426Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.Cancer Biol Ther2009
19396818EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.Cancer2009
19127119Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox.Cancer Biol Ther2009
18314475Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.J Natl Cancer Inst2008
19092150Dicer, Drosha, and outcomes in patients with ovarian cancer.N Engl J Med2008
18765535Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.Clin Cancer Res2008
18953435Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.Neoplasia2008
18519766HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.Clin Cancer Res2008
17210709Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.Cancer Res2007
17909042Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.Cancer Res2007
18006843Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.Cancer Res2007
17974982Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.Cancer Res2007
18094433Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.Clin Cancer Res2007
17545551Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.Clin Cancer Res2007
17634550Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.Clin Cancer Res2007
17308118Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.Cancer Res2007
17363522Relaxin promotes prostate cancer progression.Clin Cancer Res2007
17154180EphA2 overexpression is associated with angiogenesis in ovarian cancer.Cancer2007
16322684The role of relaxin in endometrial cancer.Cancer Biol Ther2006
17108216Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.Ann N Y Acad Sci2006
17106249Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.Cancer Biol Ther2006
17077358Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.J Natl Cancer Inst2006
16969087Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.Cancer Biol Ther2006
16969071Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.Cancer Biol Ther2006
  • 1 - 50 of 66

Recommended Authors

Yingmei Wang
Tianjin Medical University General Hospital
Career Start Year 2007
Number of shared co-authors 2
Yovanni Casablanca
Uniformed Services of the Health Sciences Gynecologic Cancer Center of Excellence
Career Start Year 2007
Number of shared co-authors 2
Divya Gupta
Emory University School of Medicine
Career Start Year 2006
Number of shared co-authors 1
Donal J Brennan
National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital
Career Start Year 2005
Number of shared co-authors 1
Robyn A Sayer
Westmead Hospital
Career Start Year 2003
Number of shared co-authors 0
Sven Mahner
University Hospital
Career Start Year 2002
Number of shared co-authors 1
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 1
Douglas A Levine
Perlmutter Cancer Center
Career Start Year 1999
Number of shared co-authors 6
Paulette Mhawech-Fauceglia
University of Southern California
Career Start Year 1995
Number of shared co-authors 3
Jacqueline F Donoghue
University of Melbourne
Career Start Year 1995
Number of shared co-authors 0
Yong-Man Kim
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1994
Number of shared co-authors 0
Denise C Connolly
Fox Chase Cancer Center
Career Start Year 1993
Number of shared co-authors 2
Ernst Lengyel
University of Chicago
Career Start Year 1993
Number of shared co-authors 2
Rosalind Glasspool
University of Glasgow
Career Start Year 1992
Number of shared co-authors 1
Sandra Orsulic
David Geffen School of Medicine, University of California at Los Angeles
Career Start Year 1992
Number of shared co-authors 3
George L Maxwell
Women's Health Integrated Research Center, Inova Health System
Career Start Year 1992
Number of shared co-authors 2
Mai Nguyen
University of California Riverside
Career Start Year 1992
Number of shared co-authors 1
Kathleen M Darcy
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Career Start Year 1990
Number of shared co-authors 2
Gustavo C Rodriguez
Clinica Quirurgica 2 (Surgical Clinic 2), Hospital Maciel
Career Start Year 1990
Number of shared co-authors 3
Tanja Pejovic
Oregon Health & Science University
Career Start Year 1989
Number of shared co-authors 3
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 0
Fr??d??ric Amant
Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 0
Cyril B Gilks
University of British Columbia
Career Start Year 1987
Number of shared co-authors 3
Gary L Keeney
Mayo Clinic
Career Start Year 1984
Number of shared co-authors 2
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 1
Andrew Berchuck
Duke School of Medicine
Career Start Year 1983
Number of shared co-authors 5
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 1
Ronny Drapkin
University of Pennsylvania School of Medicine
Career Start Year 1980
Number of shared co-authors 3
Anna DeFazio
Westmead Hospital
Career Start Year 1972
Number of shared co-authors 3

Collaborators

Anil K Sood
The University of Texas MD Anderson Cancer Center
Co-authored papers 41
Settara C Chandrasekharappa
National Institutes of Health
Co-authored papers 10
Rosemarie Schmandt
The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center
Co-authored papers 8
Frank X Donovan
National Institutes of Health
Co-authored papers 7
Agata Smogorzewska
Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12)
Co-authored papers 5
Danielle C Kimble
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 5
Francis P Lach
The Rockefeller University.
Co-authored papers 5
Arleen D Auerbach
The Rockefeller University
Co-authored papers 5
Benjamin D Solomon
Co-authored papers 4
James C Mullikin
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 4
Daniel E Pineda-Alvarez
Invitae Corporation
Co-authored papers 4
Erica Sanborn
The Rockefeller University
Co-authored papers 3
Elaine A Ostrander
National Cancer Institute
Co-authored papers 3
Elizabeth K Flynn
University of Michigan ann arbor
Co-authored papers 3
Menashe Bar-Eli
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Michael J Birrer
Co-authored papers 2
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 2
Alice C Young
Co-authored papers 2
Nancy F Hansen
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 2
Kathleen M Schmeler
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Rakesh Kumar
Rutgers New Jersey Medical School
Co-authored papers 1
Shurjo K Sen
Louisiana State University
Co-authored papers 1
Narisu Narisu
Co-authored papers 1
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 1
David C Corney
Co-authored papers 1
Susan C Modesitt
University of Virginia, Emily Couric Clinical Cancer Center
Co-authored papers 1
Lora H Ellenson
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Supawat Thongthip
University of California san francisco
Co-authored papers 1
Michael F McNitt-Gray
University of California los angeles
Co-authored papers 1
Gabriel J Villares
University of St. Thomas
Co-authored papers 1
Release 1.2